Prolonged response to PIK3CA inhibition in an advanced hormone-positive breast cancer patient with 3 mutations in the alpha subunit of PI-3 kinase.

Abstract

Mutations in the oncogene PIK3CA are implicated in many types of solid tumors and are prevalent in estrogen-receptor (ER)-positive Her2-negative (ER+Her2-) breast cancer (BC). In recent years, a combination of a drug-modulating ER and a PIK3CA inhibitor was approved for PIK3CA-mutant BC. We present a case of a 69-year-old otherwise healthy woman who was diagnosed with early ER+Her2- BC at the age of 47 and was treated with lumpectomy, adjuvant chemotherapy, radiation, and adjuvant tamoxifen. Five years after the termination of chemotherapy, she was diagnosed with bone metastasis and received several lines of endocrine therapy and subsequent capecitabine for 17 years altogether. Upon disease progression in the liver and lung, a "liquid biopsy" from the blood detected 3 missense mutations in PIK3CA, one of which was known to be deleterious (H1047R). The patient started a combination of Fulvestrant and Alpelisib with a deep and prolonged clinical and radiological response for 3 years. The occurrence of multiple mutations in PIK3CA was documented in 12-15% of BCs. A retrospective analysis showed that ER+Her2- BC patients with multiple PIK3CA mutations had a significantly higher response rate to PIK3CA inhibitor. It is impossible to determine whether our patient's extremely prolonged progression-free survival on Alpelisib-Fulvestrant was a result of the multiplicity of mutations in PIK3CA, the existence of the known deleterious mutation H1047R, or other clinical/biological factors. Our case highlights the potential importance of the number of PIK3CA mutations observed in a pathological sample or liquid biopsy, despite it being still unknown how to incorporate the multiplicity or singularity of PIK3CA mutations into clinical decision-making.